Loading
Liver Disease Diagnosis and Treatment / Diabetes, Cardiovascular Risks, and Lipoproteins · Journal article
BMC Cancer · August 14, 2026
Well-designed and adequately powered for the question it asks.
This GBD 2021-based decomposition analysis documents a major shift in China's liver cancer etiology from 1990 to 2021: viral hepatitis (HBV, HCV) burden declined significantly, while metabolic dysfunction-associated steatohepatitis (MASH)-related liver cancer rose at the fastest pace (EAPC = 0.72, 95% UI: 0.53–0.91). Risk-factor analysis shows high body mass index attribution to liver cancer DALYs increased markedly, projected to rise from 7.93% (2022) to 12.50% (2036), with sex-specific patterns favouring males in metabolic disease burden. This represents a critical public health transition requiring reorientation of prevention strategy from infectious-disease control to metabolic risk management.
Population-level burden decomposition analysis with trend estimation and Bayesian age-period-cohort projections. Chinese population; stratified by sex and etiological group (HBV, HCV, alcohol, MASLD/MASH).. China.
HBV-related liver cancer ASPR declined (EAPC = −0.15, 95% UI: −0.41 to −0.09) from 1990 to 2021 HCV-related liver cancer ASPR declined (EAPC = −0.15, 95% UI: −0.26 to −0.03) from 1990 to 2021 MASH-related liver cancer rose at fastest pace (EAPC = 0.72, 95% UI: 0.53 to 0.91)
Source does not report absolute case numbers or mortality counts, only proportional and rate-based metrics.
Clinicians and public health professionals should recognize that liver cancer prevention in China is undergoing a fundamental transition: viral hepatitis control remains essential but metabolic disease screening and early intervention—particularly for obesity and dysglycemia—now warrant parity in prevention resources and clinical attention. Sex-specific differences (male predominance in metabolic-driven burden) may guide targeted screening programs.
Rigorous population-level analysis using GBD 2021 data with quantified trends, sex-stratified findings, and validated projection methodology, demonstrating a major epidemiological shift in liver cancer etiology in China with clear effect sizes and uncertainty intervals.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians and public health professionals should recognize that liver cancer prevention in China is undergoing a fundamental transition: viral hepatitis control remains essential but metabolic disease screening and early intervention—particularly for obesity and dysglycemia—now warrant parity in prevention resources and clinical attention. Sex-specific differences (male predominance in metabolic-driven burden) may guide targeted screening programs.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Liver cancer has long ranked among the leading causes of cancer-related deaths in China. Although hepatitis B virus (HBV) and hepatitis C virus (HCV) were historically the predominant etiologies, their associated disease burden has significantly declined in recent years due to widespread vaccination and antiviral therapies. Concurrently, the burden of liver cancer originating from metabolic dysfunction–associated steatotic liver disease (MASLD), which often progresses to metabolic dysfunction–associated steatohepatitis (MASH), has risen rapidly in association with the growing prevalence of metabolic disorders such as obesity and diabetes. This suggests a structural shift in the etiological landscape of liver cancer in China. Based on data from the Global Burden of Disease Study 2021 (GBD 2021), we systematically analyzed trends from 1990 to 2021 in liver cancer burden attributable to four major causes—HBV, HCV, alcohol consumption, and MASLD—in the Chinese population. Key metrics included ASPR and disability-adjusted life years (DALYs). We further assessed DALY changes attributable to four key risk factors: high body mass index (BMI), high fasting plasma glucose (FPG), alcohol consumption, and tobacco use. Future trends from 2022 to 2036 were projected using a Bayesian age-period-cohort (BAPC) model. From 1990 to 2021, the ASPR for HBV-related liver cancer declined significantly (estimated annual percentage change [EAPC] = − 0.15, 95% uncertainty interval [UI]: − 0.41 to − 0.09), as did that for HCV-related liver cancer (EAPC = − 0.15, 95% UI: − 0.26 to − 0.03). In contrast, alcohol-related liver cancer showed a sustained increase (EAPC = 0.62, 95% UI: 0.43 to 0.81), with MASH-related liver cancer rising at the fastest pace (EAPC = 0.72, 95% UI: 0.53 to 0.91). The burden varied by sex: HBV and HCV-related liver cancer declined more significantly in females, while alcohol- and MASH-related liver cancer increased more markedly in males. Risk-attribution analysis revealed that the proportion of liver cancer DALYs attributable to high BMI rose steadily, with a pronounced increase after 2005. Projections showed that high BMI-attributable DALYs would increase from 7.93% in 2022 to 12.50% in 2036 (+ 57.7%), with a larger rise in males (+ 81.1%). Conversely, FPG-attributable burden was projected to decline by 26.8%. China is undergoing a critical transition in liver cancer prevention, shifting from infectious source control to metabolic risk management. Future strategies should strengthen metabolic screening and early intervention — particularly for high BMI and elevated FPG—while maintaining gains in viral hepatitis control. A precision management system targeting high-risk populations is urgently needed to address the growing challenge of metabolically driven liver cancer.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.